Classification
Product TypeIngredient
Product FormPowder (proteolytic enzyme preparation)
Industry PositionDietary Supplement Ingredient / Food Enzyme Preparation
Market
Bromelain in the United States is primarily a downstream consumer and formulation market, where the ingredient is used in dietary supplements and also as an enzyme preparation for food processing. U.S. market access is shaped mainly by FDA oversight of dietary supplement labeling (e.g., structure/function claims) and current good manufacturing practice (cGMP) requirements for dietary supplements. Quality expectations are commonly anchored to pharmacopeial specifications (e.g., USP–NF monograph activity units) when products are represented as conforming. Regulatory noncompliance (misbranding/adulteration or impermissible disease claims) is the most likely immediate blocker for commercialization and import clearance.
Market RoleImport-dependent consumer and formulation market
Domestic RoleLarge dietary supplement consumption market with substantial domestic manufacturing/packaging; bromelain is also used as a food enzyme preparation
Specification
Primary VarietyStem-derived bromelain (Ananas comosus)
Secondary Variety- Fruit-derived bromelain (Ananas comosus)
Physical Attributes- White to light tan amorphous powder (regulatory description for bromelain enzyme preparation in U.S. food use)
Compositional Metrics- Proteolytic activity expressed in USP Papain Units per mg (USP–NF monograph basis)
- Assay acceptance commonly expressed as a percent of labeled bromelain activity when label claims reference compendial units (USP–NF monograph context)
Grades- USP–NF dietary supplement monograph (Bromelain) conformance, when a product is represented as meeting USP standards
Supply Chain
Value Chain- Pineapple stem/fruit raw material → enzyme extraction and purification → drying to powder → bulk packaging → import/distribution into the U.S. → blending/encapsulation/tableting into finished dietary supplements
Freight IntensityLow
Transport ModeMultimodal
Risks
Regulatory Compliance HighIn the U.S., bromelain dietary supplements (and imported ingredient lots used in them) face high commercialization and border risk if labeling makes impermissible disease claims, lacks required disclaimers/notifications for structure/function claims, or fails dietary supplement cGMP controls—potentially triggering FDA enforcement actions (including detention/refusal for imports).Use only permitted dietary supplement claims with required disclaimer; submit structure/function claim notifications when applicable; maintain claim substantiation; implement 21 CFR Part 111 cGMP controls (including component identity testing and robust batch records) for bromelain-containing products.
Quality MediumBromelain is standardized by enzyme activity rather than simple mass; variability in proteolytic activity and analytical method differences can lead to potency/specification disputes and misbranding risk if label claims are not met.Align specifications and test methods to a recognized standard (e.g., USP–NF monograph activity units) where feasible; qualify suppliers; verify activity with appropriate assays and retain COAs and in-house test records.
Food Safety MediumOral bromelain is generally reported as well tolerated, but gastrointestinal side effects, drug–supplement interaction potential, and allergy/sensitivity considerations can create adverse event and reputational risk for U.S. supplement marketers.Implement adverse event monitoring and complaint handling; use clear consumer warnings consistent with product safety assessment; screen for interaction risks in product positioning and avoid implying medical treatment.
FAQ
Is bromelain permitted for use in food in the United States?Yes. U.S. regulations affirm bromelain as an enzyme preparation that can be used as a direct food ingredient to hydrolyze proteins or polypeptides under current good manufacturing practice conditions (21 CFR § 184.1024).
What is a common U.S. compendial way to specify bromelain potency?A USP–NF dietary supplement monograph specifies bromelain activity in USP Papain Units per mg and sets minimum activity expectations (e.g., not less than 1100 USP Papain Units/mg in the USP–NF monograph definition and assay context).
If a U.S. bromelain supplement label makes a structure/function claim, what extra steps are required?The claim must be truthful and not misleading, the label must include the required disclaimer stating FDA has not evaluated the claim and that the product is not intended to diagnose, treat, cure, or prevent disease, and the firm must notify FDA within 30 days after first marketing the product with the claim.